当前位置: 首页 >> 检索结果
共有 8348 条符合本次的查询结果, 用时 2.3678684 秒

61. A Nationwide Factorial Randomized Trial of Electronic Nudges to Patients with Chronic Kidney Disease and Their General Practices for Increasing Guideline-Directed Medical Therapy: The NUDGE-CKD Trial.

作者: Kristoffer Grundtvig Skaarup.;Niklas Dyrby Johansen.;Lisbet Brandi.;Morten Kofod Lindhardt.;Jesper N Bech.;My Svensson.;Tilde Kristensen.;Anne Daugaard Thuesen.;Majbritt Grønborg Knudsen.;Jan Dominik Kampman.;Mads Hornnum.;Birgitte Ørts.;Daniel Modin.;Mats C H Lassen.;Kira Hyldekær Janstrup.;Brian L Claggett.;Muthiah Vaduganathan.;Ankeet S Bhatt.;Harriette G C Van Spall.;Jens Ulrik Stæhr Jensen.;Faiez Zannad.;Scott D Solomon.;Anne Møller.;Rikke Borg.;Henrik Birn.;Ditte Hansen.;Tor Biering-Sørensen.
来源: Circulation. 2025年
Many individuals with chronic kidney disease (CKD) face considerable but modifiable risk of cardiovascular and renal outcomes due to suboptimal implementation of guideline-directed medical therapy (GDMT). We investigated whether electronic letter-based nudges delivered to individuals with CKD and their general practices could increase GDMT uptake.

62. Real-World Safety Profile of the Extravascular (EV) Implantable Defibrillator System: Insights From the MAUDE Database.

作者: Anish S Shah.;Marc Engels.;Roger A Freedman.;Immo Lehmann.;Klitos Konstantinidis.;Ravi Ranjan.;T Jared Bunch.
来源: Circ Arrhythm Electrophysiol. 2025年e013831页

63. ALPK3 Heterozygous Truncating Variants Cause Late-Onset Hypertrophic Cardiomyopathy With Frequent Apical Involvement and Apical Aneurysm.

作者: Leora Busse.;Emily A Huth.;Maria Roselle Abraham.;Theodore Abraham.;Arun Padmanabhan.;Julianne Wojciak.;Gabrielle Wright.;Rajani Aatre.;Rachel Campagna.;Erika Jackson.;Sarah Kreykes.;Kimberly Lane.;Lindsey Sawyer.;Chelsea Pappas.;Matthew Thomas.;Rebecca VanDyke.;Vasanth Vedantham.;Emily J Higgs.
来源: Circ Genom Precis Med. 2025年e005186页

64. High Dietary Phosphate Intake Induces Hypertension and Sympathetic Overactivation Through Central Fibroblast Growth Factor Receptor Signaling.

作者: Han-Kyul Kim.;Ayumi Fukazawa.;Scott A Smith.;Masaki Mizuno.;Beverly A Rothermel.;Teppei Fujikawa.;Marco Galvan.;Laurent Gautron.;Johanne V Pastor.;Isabelle Carroll.;Orson W Moe.;Wanpen Vongpatanasin.
来源: Circulation. 2025年
Recent studies have highlighted the deleterious role of high phosphate intake in hypertension by means of sympathetic overactivation, yet the underlying mechanisms remain unclear. Dietary phosphate loading triggers physiologic release of FGF23 (fibroblast growth factor-23) from the bone to maintain phosphate homeostasis. Both FGF23 and FGF receptors (FGFRs) are present in the central nervous system, but their role in neural control of blood pressure during phosphate loading is unknown. We investigated central FGF23/FGFR signaling in high-phosphate diet-induced sympathetic dysregulation of blood pressure in rats.

65. Burden of Cardiovascular Outcomes After SARS-CoV-2 Infection in South Korea and Japan: A Binational Population-Based Cohort Study.

作者: Sooji Lee.;Seung Ha Hwang.;Seoyoung Park.;Yejun Son.;Soeun Kim.;Hyeon Jin Kim.;Jaeyu Park.;Hyesu Jo.;Kyeongmin Lee.;Jiyeon Oh.;Min Seo Kim.;Damiano Pizzol.;Lee Smith.;Jinseok Lee.;Ho Geol Woo.;Hayeon Lee.;Dong Keon Yon.
来源: Circulation. 2025年
Despite the significant global impact of the COVID-19 pandemic, limited studies have investigated the long-term cardiovascular sequelae of SARS-CoV-2 infection, particularly among Asian populations. This large-scale, population-based binational cohort study with long-term follow-up aimed to investigate the association between SARS-CoV-2 infection and the risk of cardiovascular events.

66. Left Atrial to Left Ventricular Volume Ratio in Patients With Severe Functional Mitral Regurgitation.

作者: Sophia Koschatko.;Gregor Heitzinger.;Noemi Pavo.;Georg Spinka.;Suriya Prausmüller.;Katharina Mascherbauer.;Varius Dannenberg.;Christoph Torrefranca.;Matthias Koschutnik.;Carolina Donà.;Raphael Rosenhek.;Charlotte Jantsch.;Kseniya Halavina.;Laurenz Hauptmann.;Rayyan Hemetsberger.;Christian Nitsche.;Caglayan Demirel.;Christian Hengstenberg.;Martin Hülsmann.;Georg Goliasch.;Philipp E Bartko.
来源: Circ Cardiovasc Imaging. 2025年e017872页
Severe functional mitral regurgitation (fMR) is a heterogenous disease that exhibits different underlying pathophysiological mechanisms and represents independent entities. The aim of this study was to characterize remodeling patterns defined by the left atrial (LA) to left ventricular (LV) volume ratio in patients with severe fMR and heart failure, and to examine its prognostic implications.

67. Machine Learning to Automatically Differentiate Hypertrophic Cardiomyopathy, Cardiac Light Chain, and Cardiac Transthyretin Amyloidosis: A Multicenter CMR Study.

作者: Lukas Damian Weberling.;Andreas Ochs.;Mitchel Benovoy.;Fabian Aus dem Siepen.;Janek Salatzki.;Evangelos Giannitsis.;Chong Duan.;Kevin Maresca.;Yao Zhang.;Jan Möller.;Silke Friedrich.;Stefan Schönland.;Benjamin Meder.;Matthias G Friedrich.;Norbert Frey.;Florian André.
来源: Circ Cardiovasc Imaging. 2025年e017761页
Cardiac amyloidosis is associated with poor outcomes and is caused by the interstitial deposition of misfolded proteins, typically ATTR (transthyretin) or AL (light chains). Although specific therapies during early disease stages exist, the diagnosis is often only established at an advanced stage. Cardiovascular magnetic resonance (CMR) is the gold standard for imaging suspected myocardial disease. However, differentiating cardiac amyloidosis from hypertrophic cardiomyopathy may be challenging, and a reliable method for an image-based classification of amyloidosis subtypes is lacking. This study sought to investigate a CMR machine learning (ML) algorithm to identify and distinguish cardiac amyloidosis.

68. Aortic Aneurysm Risk and Somatic JAK2V617FVariation: Insights From a Multicenter, Population-Based Cardiovascular Screening Study.

作者: Lasse M Obel.;Joachim S Skovbo.;Axel C P Diederichsen.;Mads Thomassen.;Lasse Kjær.;Morten K Larsen.;Trine A Knudsen.;Vibe Skov.;Torben A Kruse.;Mark Burton.;Maja Dembic.;Troels Wienecke.;Maria Sabater-Lleal.;Oke Gerke.;Niels E Bruun.;Christina Ellervik.;Mette Brabrand.;Flemming H Steffensen.;Lars Frost.;Jess Lambrechtsen.;Martin Busk.;Grazina Urbonaviciene.;Kenneth Egstrup.;Marek Karon.;Søren Feddersen.;Lars M Rasmussen.;Hans C Hasselbalch.;Jes S Lindholt.
来源: Circulation. 2025年
The somatic JAK2V617F sequence variation, a key driver of myeloproliferative neoplasms, has been associated with increased risk of aortic aneurysms. This study aimed to explore associations between the JAK2V617F variant allele frequency (VAF) and ascending, descending, and abdominal aortic aneurysms.

69. Joint Exposure to Ozone and Temperature and Acute Myocardial Infarction Among Adults Aged 18 to 64 Years in the United States.

作者: Lingzhi Chu.;Rong Wang.;Cary P Gross.;Jing Wei.;Yuan Lu.;Harlan M Krumholz.;Xiaomei Ma.;Kai Chen.
来源: Circulation. 2025年
Previous research suggests that exposures to air pollution and nonoptimal temperatures are associated with a higher risk of acute myocardial infarction (AMI), but few studies examined the exposures jointly. Furthermore, moderate exposures were often overlooked. We evaluated short-term exposure to ambient ozone pollution and ambient temperature jointly and over the entire range of exposures, with the occurrence of AMI among adults aged 18 to 64 years (an understudied population) in the contiguous United States.

70. Biomarkers to Guide the Timing of Aortic Valve Replacement in Asymptomatic Aortic Stenosis: Where Do We Stand After Early TAVR?

作者: Jarett D Berry.;James A de Lemos.
来源: Circulation. 2025年151卷22期1565-1567页

71. Letter by Zhang and Zeng Regarding Article, "Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry".

作者: Qing Zhang.;Qingshi Zeng.
来源: Circulation. 2025年151卷22期e1043-e1044页

72. Hierarchical Composite Outcomes and Win Ratio Methods in Cardiovascular Trials: A Review and Consequent Guidance.

作者: John Gregson.;Dylan Taylor.;Ruth Owen.;Tim Collier.;David J Cohen.;Stuart Pocock.
来源: Circulation. 2025年151卷22期1606-1619页
The win ratio is a method for analyzing a hierarchical composite outcome. It has been most widely used in randomized clinical trials (RCTs) in cardiovascular disease. We performed a review of cardiovascular RCTs using the win ratio published between January 2022 and July 2024. The aims were to summarize current use and to provide examples to illustrate effective use and communication. We identified 36 eligible RCTs, mainly in heart failure and ischemic heart disease. Intervention was pharmaceutical in 26, a procedure in 7, and treatment strategy in 3 trials. When outcomes were analyzed with both conventional composite end points or hierarchical analysis, the conclusions tended to be similar. The win ratio was often used to combine evidence from event outcomes and quantitative measures together in a hierarchical composite, as was done in 23 RCTs. It was also used to create a clinically more relevant measure in RCTs by recognizing the clinical priorities among event outcomes. Selected example RCTs illustrate how the clarity of win ratio findings can be improved by (1) complementing the win ratio (a relative measure) with the win difference, (2) identifying which components of a hierarchical composite drive the overall results, and (3) clearly prespecifying the outcomes and win ratio analysis to be used. We conclude with a set of recommendations for future use of hierarchical composite outcomes and the win ratio. When used wisely, the win ratio is a valuable tool in the analysis of RCTs.

73. Population Screening With Natriuretic Peptides Is Ready for Prime Time.

作者: Antoni Bayés-Genis.
来源: Circulation. 2025年151卷22期1547-1549页

74. TET2-Mutant Clonal Hematopoiesis Promotes Heart Failure With Preserved Ejection Fraction.

作者: Ambarish Pandey.;Toby Thomas.;Yuanyuan Ji.;Benjamin Kroger.;Peter Carlsgaard.;Camila I Irion.;Fatma Kalkan.;Matthew Segar.;Vinayak Subramanian.;Antoni Bayés-Genís.;Albert Son.;Kira A Young.;Jennifer J Trowbridge.;Naveen Premnath.;Nan Jiang.;Daniel Daou.;Wenhuo Hu.;Sarah A Ware.;Dan Tong.;Stephen S Chung.
来源: Circulation. 2025年151卷22期1622-1625页

75. Response by Maurizi et al to Letter Regarding Article, "Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry".

作者: Niccolò Maurizi.;Panagiotis Antiochos.;Sharlene M Day.;Iacopo Olivotto.
来源: Circulation. 2025年151卷22期e1045-e1046页

76. Impact of Initial Extensive Ablation on Left Atrial Gaps During Redo Procedures and Subsequent Outcomes in Persistent Atrial Fibrillation.

作者: Masato Okada.;Koichi Inoue.;Nobuaki Tanaka.;Masaharu Masuda.;Tetsuya Watanabe.;Nobuhiko Makino.;Yasuyuki Egami.;Takafumi Oka.;Hitoshi Minamiguchi.;Miwa Miyoshi.;Takashi Kanda.;Yasuhiro Matsuda.;Masato Kawasaki.;Koji Tanaka.;Yuko Hirao.;Shungo Hikoso.;Akihiro Sunaga.;Tomoharu Dohi.;Daisaku Nakatani.;Katsuki Okada.;Yohei Sotomi.;Yasushi Sakata.; .
来源: Circ Arrhythm Electrophysiol. 2025年18卷6期e013612页
The efficacy of extensive linear ablation strategies, in addition to pulmonary vein (PV) isolation, remains controversial in persistent atrial fibrillation (AF) ablation. Gaps in previously ablated lesions can induce arrhythmias and potentially decrease the effectiveness of extensive ablation. This study evaluated the incidence of conduction gaps, gap-related reentry, and subsequent recurrence following redo AF ablation in the EARNEST-PVI trial (Efficacy of Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation; REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03514693).

77. Evaluation of Bioprosthetic Valve Dysfunction in the SMART Randomized Clinical Trial.

作者: Howard C Herrmann.;Daniel J Blackman.;Guilherme F Attizzani.;Mohamed Abdel-Wahab.;Wayne B Batchelor.;Linda D Gillam.;Toby Rogers.;Jae K Oh.;Andrew D Althouse.;Roxana Mehran.;Didier Tchétché.
来源: Circ Cardiovasc Interv. 2025年e015202页

78. Pulmonary Circulation in Advanced Heart Failure and Cardiogenic Shock: State-of-the-Art Review.

作者: Sara L Hungerford.;Kay Everett.;Edmund Lau.;Daniel Burkhoff.;Navin K Kapur.
来源: Circ Heart Fail. 2025年e012611页
The pulsatile nature of blood flow and the hydrostatic effect of pulmonary capillary wedge pressure are 2 fundamental, yet often overlooked features of right ventricular-pulmonary arterial interactions in advanced heart failure and cardiogenic shock. These 2 features (above all others) define both the mechanical forces experienced by the pulmonary arteries, and in turn, the vascular afterload imposed by the pulmonary circulation on the right ventricular. For over half a century, it has been assumed that the pulsatile components of the pulmonary circulation exist in predictable and constant proportion to resistive afterload. In other words, that the vascular afterload can be estimated from mean pulmonary arterial pressure and pulmonary vascular resistance alone. While this tenet holds true for most forms of pulmonary hypertension, pulmonary hypertension resulting from the passive transmission of elevated left atrial pressure is a notable exception. In these cases, arterial compliance decreases proportionally more than any increase in pulmonary vascular resistance and is highly dependent upon recruitment and distensibility of the pulmonary circulation. As questions regarding the optimal method to predict right ventricular failure resurface, along with a modern armamentarium of techniques to assess pulsatile pressure-flow relations, it serves as a timely reminder that, in those with normal or near-normal pulmonary arterial pressures, the pulsatile component of pulmonary vascular afterload may account for anywhere between one-quarter and half of the total power of the right ventricular. In this State-of-the-Art Review, we address the role of pulmonary circulation in those with advanced heart failure and cardiogenic shock. Unlike previous discussions on this topic, we set aside considerations of established precapillary disease, focusing specifically on the process by which an acute or chronic elevation of pulmonary capillary wedge pressure results in pulmonary hypertension from left-sided heart failure. In doing so, we create a framework to assess pulmonary vascular afterload in an era of advanced therapeutics and device technologies to treat advanced heart failure and cardiogenic shock.

79. Letter by Manuel Regarding Article, "Progressive LV Dysfunction and Adverse Outcomes After Aortic Valve Replacement With Bioprosthetic Valves in Young Patients".

作者: Valdano Manuel.
来源: Circ Cardiovasc Imaging. 2025年e018428页

80. Unfolding Evidence on Risk Stratification in Women Using Quantitative Atherosclerotic Plaque Measurements.

作者: Leslee J Shaw.;Fay Y Lin.
来源: Circ Cardiovasc Imaging. 2025年18卷6期e018438页
共有 8348 条符合本次的查询结果, 用时 2.3678684 秒